Fields like dermatology, once considered too operationally expensive and services-heavy for venture scale, are now attractive investment areas. AI enables scalable solutions for remote diagnostics, personalized treatment plans, and progress tracking, reducing capital expenditure and unlocking a massive consumer spend category.

The overactive bladder market is chronically underserved not due to a lack of options, but because existing treatments (drugs linked to dementia, expensive implants) are so flawed that 78% of patients refuse them. This massive patient drop-off signals a prime opportunity for safer, more accessible alternatives.

While hype cycles focus on novel areas, significant value exists in established markets like hypertension. By targeting refractory patient populations with high unmet needs (e.g., the 20% of hypertension patients not properly treated), biotechs can create valuable assets with novel mechanisms in fields that appear saturated.

Eli Lilly's market dominance stems from its 2018 bet on obesity drugs, a field then considered a 'non-market.' Their philosophy is that by the time a medical market is large and obvious, it's too late to invest in R&D. They prioritize investing where the science is profound, not where the market currently is.

The CEO contrasts top drugs from 2000 (high-volume, mass-market) with 2020 (low-volume, high-price). He predicts the industry will see a resurgence in value creation from high-volume, lower-price markets like obesity, marking a significant reversal of a decades-long trend toward niche specialty medicines.

The biotech industry is currently a "disease industry." The largest future markets, like GLP-1 drugs for weight loss, will target healthy consumers seeking enhancements in lifespan, sleep, or appearance. This represents a fundamental shift to a consumer-driven, preventative health model.

Upcoming oral psoriasis drugs from J&J, Alumis, and Takeda offer efficacy close to injectables but with greater convenience. This strategy is not about stealing market share but about massive market expansion, targeting millions of patients using only topicals and potentially growing the market to over $40 billion.

While new technology is a factor, renewed investment in neuroscience is heavily driven by its "greenfield" status. Unlike crowded markets like oncology, many neurological disorders lack effective treatments, offering significant, untapped commercial potential for large pharmaceutical companies seeking new growth areas.

The strategy is to acquire biotech companies at valuations justified by a narrow clinical indication (e.g., premature ejaculation). The massive return comes from the "free option" of the much larger off-label consumer market (e.g., all men wanting to last longer) that is not priced in.